Integrated Discovery Engine
Utilizing our integrated discovery engine to efficiently identify and develop novel oncology therapies
Leveraging our deep industry experience and knowledge, we have built our Integrated Discovery Engine, which combines our extensive capabilities across cancer biology and medicinal chemistry. We utilize this discovery engine to identify targets and develop small molecules that we believe could have potentially differentiated product candidate profiles. Our advanced approach has allowed us to successfully clear four INDs with the FDA within five years. This approach for synthesizing compounds, from identification to IND, is highly efficient.
Integrated Discovery Engine Process
First, we assess fundamental biological pathways of cancer, considering a number of factors, including clinical validation, unmet medical need and market opportunity. Our initial strategy is to focus on targets that have been proven clinically, and in some instances, commercially. As a result, we are able to start our drug discovery and development at an advanced stage.
Second, we evaluate key chemical scaffolds targeting the identified cancer pathways and assess their limitations, including efficacy, safety, tolerability, PK, patient convenience and their potential to be used in combination.
Third, we use our medicinal chemistry expertise and deep understanding of target-drug structure activity relationships to create new molecules that are designed to improve upon and address observed constraints of existing products or compounds.
Fourth, we generate strong preclinical data to show that our chosen candidate may have differentiated product profiles from current research programs or commercial products targeting similar pathways.